Wayne Godfrey - Jun 10, 2021 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Medical Officer
Signature
/s/ Tighe Reardon, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jun 10, 2021
Transactions value $
$0
Form type
3
Date filed
6/10/2021, 07:24 PM
Next filing
Jan 5, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock Option (right to buy) Jun 10, 2021 Common Stock 448K $10.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares vest one year after May 14, 2021 (the "Vesting Commencement Date"); the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.